The coronavirus pandemic propelled innovators in healthcare and life sciences to develop and manufacture diagnostics, vaccines and treatments at incredible speed. Pharma companies in Europe and around the world benefited from pre-existing infrastructure, cross-industry collaboration and a flexible policy environment – something to be cherished and strengthened. 

Technology is transforming healthcare and pharma innovation is stronger than ever. In Europe, the scope for bringing technology and innovation to patients is defined by both the pharma industry and policymakers. Each have a role to play in creating an environment that supports medical breakthroughs. 

Join us as we discuss the challenges of creating a new pharma innovation ecosystem in Europe, one capable of attracting global life science investors to develop and manufacture the next generation of diagnostics, vaccines and treatments.

Understand

The big picture, not just the individual strands of the business you work in

Connect

And build relationships with some of the biggest names in your industry

Discover

New approaches and strategies to help win market share

Premier Digital Events supported by the world's best journalism

Using leading digital technology, we have now taken our content, global audience reach and engagement to a new level through a series of unmissable virtual events. Our compelling events are chaired by respected FT journalists, feature the most senior and thought-provoking decision-makers in business, finance and politics, all accessible from your office or home.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice